Phase II evaluation of BCNU and 5-FU in gastrointestinal carcinomas.
D000230:Adenocarcinoma / Q000188:drug therapy*; D000284:Administration, Oral; D002330:Carmustine / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D003110:Colonic Neoplasms / Q000188:drug therapy*; D003967:Diarrhea / Q000139:chemically induced; D005472:Fluorouracil / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D006400:Hematocrit; D006801:Humans; D007275:Injections, Intravenous; D007970:Leukopenia / Q000139:chemically induced; D009325:Nausea / Q000139:chemically induced; D009362:Neoplasm Metastasis; D009607:Nitrosourea Compounds / Q000008:administration & dosage / Q000627:therapeutic use; D013274:Stomach Neoplasms / Q000188:drug therapy*; D013921:Thrombocytopenia / Q000139:chemically induced; D013997:Time Factors; D014839:Vomiting / Q000139:chemically induced
D009607:Nitrosourea Compounds; D005472:Fluorouracil; D002330:Carmustine